329 related articles for article (PubMed ID: 25963334)
1. CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients.
Maganda BA; Minzi OM; Ngaimisi E; Kamuhabwa AA; Aklillu E
Pharmacogenomics J; 2016 Feb; 16(1):88-95. PubMed ID: 25963334
[TBL] [Abstract][Full Text] [Related]
2. The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment.
Maganda BA; Ngaimisi E; Kamuhabwa AA; Aklillu E; Minzi OM
Malar J; 2015 Apr; 14():179. PubMed ID: 25906774
[TBL] [Abstract][Full Text] [Related]
3. Outcome of artemether-lumefantrine treatment for uncomplicated malaria in HIV-infected adult patients on anti-retroviral therapy.
Maganda BA; Minzi OM; Kamuhabwa AA; Ngasala B; Sasi PG
Malar J; 2014 May; 13():205. PubMed ID: 24885714
[TBL] [Abstract][Full Text] [Related]
4. Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women.
Mutagonda RF; Kamuhabwa AAR; Minzi OMS; Massawe SN; Asghar M; Homann MV; Färnert A; Aklillu E
Malar J; 2017 Jul; 16(1):267. PubMed ID: 28673292
[TBL] [Abstract][Full Text] [Related]
5. Effect of nevirapine, efavirenz and lopinavir/ritonavir on the therapeutic concentration and toxicity of lumefantrine in people living with HIV at Lagos University Teaching Hospital, Nigeria.
Usman SO; Oreagba IA; Akinyede AA; Agbaje EO; Akinleye MO; Onwujuobi AG; Ken-Owotor C; Adeuja O; Ogunfowokan T; Kogbe S; Owolabi ET; Adeniji H; Busari AW; Hassan OO; Abideen G; Akanmu AS
J Pharmacol Sci; 2020 Nov; 144(3):95-101. PubMed ID: 32921396
[TBL] [Abstract][Full Text] [Related]
6. Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children.
Parikh S; Kajubi R; Huang L; Ssebuliba J; Kiconco S; Gao Q; Li F; Were M; Kakuru A; Achan J; Mwebaza N; Aweeka FT
Clin Infect Dis; 2016 Aug; 63(3):414-22. PubMed ID: 27143666
[TBL] [Abstract][Full Text] [Related]
7. HIV-positive nigerian adults harbor significantly higher serum lumefantrine levels than HIV-negative individuals seven days after treatment for Plasmodium falciparum infection.
Chijioke-Nwauche I; van Wyk A; Nwauche C; Beshir KB; Kaur H; Sutherland CJ
Antimicrob Agents Chemother; 2013 Sep; 57(9):4146-50. PubMed ID: 23774430
[TBL] [Abstract][Full Text] [Related]
8. Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy.
Parikh S; Fehintola F; Huang L; Olson A; Adedeji WA; Darin KM; Morse GD; Murphy RL; Taiwo BO; Akinyinka OO; Adewole IF; Aweeka FT; Scarsi KK
Antimicrob Agents Chemother; 2015 Dec; 59(12):7852-6. PubMed ID: 26392500
[TBL] [Abstract][Full Text] [Related]
9. Influence of selected polymorphisms in disposition genes on lumefantrine pharmacokinetics when coadministered with efavirenz.
Adegbola AJ; Rana A; Adeagbo BA; Bolarinwa RA; Olagunju AE; Siccardi M; Owen A; Bolaji OO
Pharmacogenet Genomics; 2020 Jul; 30(5):96-106. PubMed ID: 32209837
[TBL] [Abstract][Full Text] [Related]
10. Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients.
Kredo T; Mauff K; Van der Walt JS; Wiesner L; Maartens G; Cohen K; Smith P; Barnes KI
Antimicrob Agents Chemother; 2011 Dec; 55(12):5616-23. PubMed ID: 21947399
[TBL] [Abstract][Full Text] [Related]
11. Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals.
Heil SG; van der Ende ME; Schenk PW; van der Heiden I; Lindemans J; Burger D; van Schaik RH
Ther Drug Monit; 2012 Apr; 34(2):153-9. PubMed ID: 22354160
[TBL] [Abstract][Full Text] [Related]
12. High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort study.
Yimer G; Amogne W; Habtewold A; Makonnen E; Ueda N; Suda A; Worku A; Haefeli WE; Burhenne J; Aderaye G; Lindquist L; Aklillu E
Pharmacogenomics J; 2012 Dec; 12(6):499-506. PubMed ID: 21862974
[TBL] [Abstract][Full Text] [Related]
13. A fast and reliable reversed phase high performance liquid chromatography method for simultaneous determination of selected anti-retroviral and lumefantrine in human plasma.
Maganda B; Heudi O; Cortinovis A; Picard F; Kretz O; Minzi O
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Mar; 919-920():52-60. PubMed ID: 23411019
[TBL] [Abstract][Full Text] [Related]
14. Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults.
Byakika-Kibwika P; Lamorde M; Mayito J; Nabukeera L; Namakula R; Mayanja-Kizza H; Katabira E; Ntale M; Pakker N; Ryan M; Hanpithakpong W; Tarning J; Lindegardh N; de Vries PJ; Khoo S; Back D; Merry C
J Antimicrob Chemother; 2012 Sep; 67(9):2213-21. PubMed ID: 22687893
[TBL] [Abstract][Full Text] [Related]
15. CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure.
Mukonzo JK; Nanzigu S; Waako P; Ogwal-Okeng J; Gustafson LL; Aklillu E
Pharmacogenomics; 2014 Aug; 15(11):1423-35. PubMed ID: 25303294
[TBL] [Abstract][Full Text] [Related]
16. Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis.
Ngaimisi E; Mugusi S; Minzi O; Sasi P; Riedel KD; Suda A; Ueda N; Janabi M; Mugusi F; Haefeli WE; Bertilsson L; Burhenne J; Aklillu E
Clin Pharmacol Ther; 2011 Sep; 90(3):406-13. PubMed ID: 21814190
[TBL] [Abstract][Full Text] [Related]
17. The impact of CYP2B6 polymorphisms on the interactions of efavirenz with lumefantrine: Implications for paediatric antimalarial therapy.
Zakaria Z; Badhan RKS
Eur J Pharm Sci; 2018 Jul; 119():90-101. PubMed ID: 29635009
[TBL] [Abstract][Full Text] [Related]
18. CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe.
Dhoro M; Zvada S; Ngara B; Nhachi C; Kadzirange G; Chonzi P; Masimirembwa C
BMC Pharmacol Toxicol; 2015 Mar; 16():4. PubMed ID: 25889207
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients.
Habtewold A; Aklillu E; Makonnen E; Yimer G; Bertilsson L; Burhenne J; Owen JS
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559276
[TBL] [Abstract][Full Text] [Related]
20. Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations.
Ngaimisi E; Habtewold A; Minzi O; Makonnen E; Mugusi S; Amogne W; Yimer G; Riedel KD; Janabi M; Aderaye G; Mugusi F; Bertilsson L; Aklillu E; Burhenne J
PLoS One; 2013; 8(7):e67946. PubMed ID: 23861838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
